The recreational effects of this compound occur because opioids structurally mimic endogenous endorphins which are naturally found within the body and also work upon the μ-opioid receptor set. The way in which opioids structurally mimic these natural endorphins results in their physical euphoria, pain relief and anxiolytic effects. This is because endorphins are responsible for reducing pain, causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or general excitement.
Acetylfentanyl's strong potency in relation to that of morphine is largely due to its high lipophilicity, which is the ability of a chemical compound to dissolve in fats, oils, and lipids. Because of this, it can more easily penetrate the central nervous system in comparison to other opioids.
Acetylfentanyl, similar to fentanyl, possesses opioid-like in vitro binding affinity to µ-opioid receptors as well as produce µ-opioid receptor agonist effects. Acetylfentanyl has also been shown to inhibit the twitch response in electrically stimulated vas deferens preparation. Similarly, in another study using tail flick and phenylquinone writhing tests, acetylfentanyl produced analgesic response in mice. Acetylfentanyl has been shown to completely suppress the signs of withdrawal in morphine-dependent monkeys. Furthermore, acetylfentanyl produce morphine-like subjective effects in drug discrimination study. Besides analgesia, fentanyl-like substances, similar to other opioid analgesics, produce a variety of pharmacological effects including alteration in mood, euphoria, drowsiness, respiratory depression, suppression of cough reflex, constriction of pupils (miosis), and impaired gastrointestinal motility.
The United States Drug Enforcement Administration reported in July of 2015 that at least 52 confirmed fatalities involving acetylfentanyl in the United States had occurred between 2013-2015. Ten fatalities attributed to acetylfentanyl overdose were reported during March of 2013 alone in Rhode Island.potentially fatal at heavy dosages and even those with opiate tolerances are at high risk for overdoses. Once the acetylfentanyl is in the user's system, it is extremely difficult to stop its course because of the nature of absorption. Because of the extremely high strength of pure acetylfentanyl powder, it is very difficult to dilute appropriately, and often the resulting mixture may be far too strong and, therefore, very dangerous. It is also lethal when mixed with depressants like alcohol or benzodiazepines]].
Like most opioids, unadulterated acetylfentanyl at appropriate dosages does not cause many long-term complications other than extreme physical dependence and constipation. Outside of physical and psychological addiction, the harmful aspects of opioid usage are associated with not taking the necessary precautions in regards to its administration, overdosing on the substance and using impure products within the substance. It is important to consider that particular care must be taken with acetylfentanyl due to its extreme potency and ability to be absorbed through the skin.unintentionally spilling a very small amount of acetylfentanyl on one's skin could result in a fatal overdose.
Heavy dosages of acetylfentanyl can result in respiratory depression, leading onto fatal or dangerous levels of anoxia (oxygen deprivation). This occurs because the breathing reflex is suppressed by agonism of μ-opioid receptor proportional to the dosage consumed.
Acetylfentanyl can also cause nausea and vomiting; a significant number of deaths attributed to opioid overdose are caused by aspiration of vomit by an unconscious victim. This is when an unconscious or semi-conscious user who is lying on their back vomits into their mouth and unknowingly suffocates. It can be prevented by ensuring that one is lying on their side with their head tilted downwards so that the airways cannot be blocked in the event of vomiting while unconscious (also known as the recovery position). In case of overdose, it is advised to administer a dose of naloxone intravenously or intramuscularly to reverse the effects of opioid agonism.
It is strongly recommended that one use harm reduction practices when using this substance.
As with other opioids,extremely addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.develops with prolonged and repeated use. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). Acetylfentanyl presents cross-tolerance with Cross-all other opioids, meaning that after the consumption of acetylfentanyl all opioids will have a reduced effect.
The risk of fatal opioid overdoses rise sharply after a period of cessation and relapse, largely because of reduced tolerance. To account for this lack of tolerance, it is safer to only dose a fraction of one's usual dosage if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of heroin administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.
In 2016, acetylfentanyl was placed under international control, in Schedule I and Schedule IV of the 1961 UN Single Convention on Narcotic Drugs.
Austria: Acetylfentanyl is a controlled substance under the SMG.
Canada: Acetylfentanyl is a Schedule 1 controlled substance as it is an analog of fentanyl.
China: Acetylfentanyl is a controlled substance as of October 1, 2015.
Cyprus: Acetylfentanyl is a controlled substance since 2013.
Estonia: Acetylfentanyl is a controlled substance as of June 8, 2015.
Finland: Acetylfentanyl is a Liite 4 (Annex 4) controlled substance as of September 28, 2015.
Germany: Acetylfentanyl is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of June 20, 2017. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Ireland: Acetylfentanyl is listed in Schedule I of the Misuse of Drugs Regulation 1988.
Latvia: Acetylfentanyl is a List I controlled substance.
Lithuania: Acetylfentanyl is a controlled substance.
Norway: Acetylfentanyl is controlled by the Medicines Act.
Poland: Acetylfentanyl is controlled under new psychoactive substances control legislation.
Russia: Acetylfentanyl is a Schedule I controlled substance.
Sweden: Acetylfentanyl is a controlled substance as of August 18, 2015.
Switzerland: Acetylfentanyl is a controlled substance specifically named under Verzeichnis D.
Turkey: Acetylfentanyl is illegal in Turkey as of February 2016.
United Kingdom: Acetylfentanyl was made a Class A controlled substance as an analogue of fentanyl in 1986.
United States: Acetylfentanyl is a Schedule I controlled substance as of May 2015. The illegality of the drug has been supported by the charges against individuals for distribution of acetylfentanyl and possession with the intent to distribute acetylfentanyl. One individual was sentenced to 3 years in prison by a federal court.
Responsible use
Volumetric liquid dosing
Opioid
Fentanyl
Heroin
Morphine
Acetylfentanyl (Wikipedia)
Acetylfentanyl (Erowid Vault)
Acetylfentanyl (Isomer Design)
Acetylfentanyl can be administered via insufflated, sublingual. The route of administration can influence both the onset and intensity of serotonin syndrome.